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4 Aristolochic acids (AAs) are a mixture of nitrophenanthrene carboxylic acid derivatives found primarily in the genus Aristolochia (Ong et al., 2000) . Major components of AAs include aristolochic acid I (8-methoxy-6-nitro-phenanthro (3,4-d)-1,3-dioxolo-5-carboxylic acid, AAI) and aristolochic acid II (6-nitro-phenanthro (3,4-d)-1,3-dioxolo-5-carboxylic acid, AAII) that differ by a methoxy group (Fig. 1) . Herbal products containing AAs have long been used for the treatment of tumour and snake bites (Kupchan and Doskotch, 1962; Rocker and Chung, 1975) . Their anti-inflammatory properties were of great interest for pharmaceutical companies in Germany for 20 years until they were observed to be carcinogenic in rats (Mengs et al., 1982) . Since then, extensive studies have been conducted in rodents for the probable human carcinogenicity (Bieler et al., 1997; Mengs, 1988; Pfau et al., 1990b Pfau et al., , 1990c Pfau et al., , 1991 Stiborova et al., 1994 Stiborova et al., , 2001 Stiborova et al., , 2002 Stiborova et al., , 2003 . The metabolic activation of AAs is a unique example of intramolecular acetylation, which leads to the ultimate carcinogen. It was postulated that an intermediate generated from nitroreduction of AAs, namely aristolactam-nitriumion with a delocalized positive charge, is the ultimate carcinogen. The aristolactam-nitriumion was found to bind to the exocyclic amino group of purine nucleotides in DNA. The DNA-AA adducts were detected in internal organs of patients suffered from the aristolochic acid nephropathy (AAN) (Bieler et al., 1997; Stiborova et al., 2002) .
It is known that carcinogenic nitroaromatics (R-NO 2 ) may be metabolized to Nhydroxylamine (R-NHOH) before being further reduced to aromatic amines (R-NH 2 ) by drug metabolism (Kato et al., 1969; Mitchelmore et al., 1998; Purohit and Basu, 2000; Sugimura et al., 1966; Tatsumi et al., 1986) and microbial activities (Hasegawa et al. 
AAs in rats were produced from nitroreduction, O-demethylation and denitration. Odemethylation and hydroxylation were also observed in aristolactam I and aristolactam II, respectively, producing aristolactam Ia as the common end-stage reductive metabolite (Chan et al., 2006; Krumbiegel et al., 1987) . The formation of hydroxylamine upon metabolic activation is believed to be the key step for the carcinogenicity. The nitroreduction plays a key role on biotransformation to the ultimate carcinogen of AAs (Pfau et al., 1990b (Pfau et al., , 1991 Schmeiser et al., 1986) . However, little is known about the mechanism underlying the bioactivation of AAs. The identification of 7-hydroxyaristolactam I after incubating AAI with xanthine oxidase led to the postulation of a reduction mechanism for AAI (Pfau et al., 1990b) . It was also proposed that the carcinogenic activity of AAs arose from their hydroxylamine (Schmeiser et al., 1986) . To the best of our knowledge, no in vivo study regarding the metabolic activation of AAs is available in the literature.
Lactam formation was the major in vivo and in vitro metabolic pathway of AAs after nitroreduction (Chan et al., 2006; Krumbiegel et al., 1987) . With the support of spectroscopic data from in vitro incubations, Pfau (1990b) postulated that AAs were metabolized to N-hydroxyaristolactam that might be further reduced to aristolactams or rearranged to 7-hydroxyaristolactams via Bamberger rearrangement. The 7-hydroxyaristolactams could also be produced from the 7-hydroxylation of the aristolactams. This paper reports results of the investigation of in vivo metabolic pathways by analyzing a series of positional isomers of hydroxyaristolactams. In addition to the LC-MS and MS-MS analyses, theoretical computations on the hydroxylated metabolites of aristolactams were also performed to help the isomer assignment. In DMD #13979
Materials and Methods

Chemicals
Aristolochic acids (mixture of AAI and AAII, 1:1 approx) were purchased from Acros Organics (NJ, USA). Aristolactam I and aristolactam II were prepared by the method described previously (Chan et al., 2006) . Acetic acid and ammonium acetate were obtained from Panreac (Barcelona, Spain). Silica-bonded C 18 solid-phase extraction (SPE) cartridges (500 mg) were obtained from Waters (Milford, USA). HPLC-grade methanol was purchased from Tedia (OH, USA). Water was produced by a Milli-Q Ultrapure water system with the water outlet operating at 18.2 MΩ (Waters, Milford, USA).
Animal experiment and sample preparation
Male Sprague-Dawley rats (n=4) weighing 200-220 g were obtained from the Laboratory Animal Service Centre, Chinese University of Hong Kong. The animals were kept in a controlled room with constant temperature (23 o C ±1) and artificial dark/light cycles. The rats were fasted for overnight but water was given ad libitum before a single oral dose of 6 mg of AAs in 0.5% NaHCO 3 solution. The dosed rats were then housed in metabolic cage which allowed the separated collection of urine and faces. The rat urine from 0 to 24 hour after the oral administration were collected and kept at -20 o C.
Urine sample after thawing was filtered through a cellulose filter disc (25 mm, 0.2 µm) prior to the SPE. 5 mL of urine was loaded onto a pre-conditioned SPE cartridge and washed sequentially with 3 mL of water, 2 mL of water/methanol (4:1) and eluted with 3 mL of methanol. The methanolic eluent were collected and evaporated to dryness under a DMD #13979 8 stream of nitrogen. The residual was dissolved in 50 µL of methanol and then centrifuged at 13,000 rpm for 3 min prior to the LC-MS analysis.
Calibration plots for the reductive metabolites of AAs were obtained from LC-MS determination of aristolactam I and aristolactam II at concentrations of 0.2, 1, 2.5, 5 and 10 µg/mL in blank urine matrix. Linear regression analysis gave calibration curves that were used to calculate the amount of aristolactam I and aristolactam II excreted in rat urine. To determine the recovery of the SPE extraction process for aristolactams, aristolactam I and aristolactam II were spiked to blank urine (2 mL) at a final concentration of 0.5 µg/mL (n=5), processed and measured in the same way as the samples from the AAs dosed rats.
LC-MS analysis
HPLC experiments were performed on a HP1100 HPLC system equipped with an 
Theoretical calculations
The structure stability, vibration frequency, total energy, relative energy and dipole moment for hydroxyaristolactams were obtained from theoretical calculations using Gaussian 03 (Revision C.02, 2004, Gaussian, Inc., Wallingford CT, USA). The geometry optimization and vibrational frequency analyses were performed by using the density functional theory (DFT) at the B3LYP/6-31G(d) level in both aqueous and gas phases.
The integral equation formalism-polarizable continuum solvation model (IEF-PCM), was used to treat the solvent effect in the aqueous phase. An empirical scaling factor of 0.9804 was used to correct the zero-point vibrational energies. The absence of imaginary frequencies in the theoretical calculations verified that all the structures were at their true minima at the specified computational level.
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Results
Quantitative analysis of aristolactams in urine samples
The synthesized standards reported previously (Chan et al., 2006) (Chan et al., 2006; Schmeiser, 1986) .
Identification of AAs metabolites
Decarboxylated metabolites of AAs
New metabolites from decarboxylation of AAs ( 
Investigations of the isobaric hydroxylated metabolites of aristolactams by theoretical calculations
Discussion
The carcinogenic and mutagenic properties of AAs have been extensively investigated.
However, only limited data on in vivo metabolism have been reported (Schmeiser, 1986; Krumbiegel, 1987 In this study, two major metabolites from the nitroreduction of AAs (aristolactam I and aristolactam II) were quantified in the rat urine. The quantitative analysis of aristolactams is of great interest not only because the lactam formation was the major in vivo and in vitro metabolic pathway of AAs after the nitroreduction (Chan et al., 2006; Krumbiegel et al., 1987) but also because the intermediates (aristolactam-nitriumion) of the reduction process plays a key role on biotransformation to the ultimate carcinogen of AAs (Pfau et al., 1990b (Pfau et al., , 1991 Schmeiser et al., 1986) . The preliminary quantitative analysis indicated that sub µg/mL level of aristolactam I and aristolactam II existed in the rat urine samples collected after the oral administration of AAs. The concentration of aristolactam II was around 2 times higher than that of aristolactam I, probably because the parent compound of aristolactam I (i.e., AAI) could be easily demethylated to aristolochic acid Ia (Fig. 1) . Being peri-substituted nitrophenanthrene carboxylic acids, AAs are weak mutagens in S.
typhimurium strain TA100 when compared with other nitroaromatic compounds (Purohit and Basu, 2000) . It has been reported that steric repulsion between the carboxyl and nitro group rendered the nitro group to deviate from co-planarity with reference to the aromatic rings (Pfau et al., 1990a) . Nitroaromatics with perpendicularly orientated nitro group has been proved to be poor substrates for nitroreductases in mutagenicity assay (Fu et al., 1985) , which might be the reason for the observed low mutagenicity of AAs. However, the decarboxylation of AAs (M1) alleviates the steric repulsion experienced by the nitro group, making it less deviated from co-planarity with reference to the aromatic rings, which might enhance their mutagenicity. complex sample matrix. In our previous study, three glucuronide conjugates of aristolactams were detected and characterized (Chan et al., 2006 ).
An extensive O-demethylation has been observed for AAI in both in vitro and in vivo
studies, producing AAIa as the metabolite (Chan et al., 2006; Krumbiegel et al., 1987; Schmeiser et al., 1986) . However, the metabolic fate of AAIa is not well understood apart from the lactam formation, which produces aristolactam Ia. Herein, we report the first The mechanism underlying N-hydroxylation of arylamines and the nitroreduction of nitropolycyclic hydrocarbons to aryl hydroxyamines has been considered common.
Similar to other nitroaromatics, nitroreduction is the crucial step in metabolic activation of AAs to their ultimate carcinogen. Being the first example of intra-molecular acetylation upon metabolic activation, the mechanism for the in vitro reductive conversion of AAI to aristolactam I was postulated (Pfau et al., 1990b) . It was proposed that AAI was first metabolized to its N-hydroxyaristolactam I, which was either reduced to aristolactam I or underwent Bamberger rearrangement to give 7-hydroxyaristolactam I.
This article has not been copyedited and formatted. The final version may differ from this version. In this study, three hydroxylated metabolites of aristolactam II (M6-M8) (Fig. 5A ) and two hydroxylated metabolites of aristolactam I (M9, M10) (Fig. 5B) were detected in the rat urine. Based on the previous metabolism study of AAs (Arlt et al., 2002; Pfau et al., 1990b) , the hydroxylated metabolites from aristolactam II (MW 279) were identified as However, distinguishing the positional isomers was challenge because the corresponding authentic standards were not available. Theoretical computation was therefore performed to help the assignment of the hydroxyaristolactams in the LC-MS chromatograms.
The reverse-phase liquid chromatographic retention time generally depends on the polarity and structural parameters (e.g., size/shape) of the eluted compounds (Kaliszan et al., 1986) . Of a congeneric series of analytes, the more polar compounds generally have less retention under the identical chromatographic conditions. The chemical polarity can be expressed in terms of electronic properties such as dipole moment and polar surface area. Compounds with larger dipole moment tend to have shorter retention time (Kaliszan et al., 1986; Niessen, 1999) . For the three hydroxylated metabolites of aristolactam II (M6-M8), the calculated dipole moments of aristolactam Ia, N-hydroxyaristolactam II and 7-hydroxyaristolactam II in the aqueous phase were 7.5, 6.1 and 4.6 Debye, respectively, with a similar orientation ( Table 1 (Table 1) . The MS-MS data under the identical collision energy were in agreement with the molecular stability represented by the calculated relative energy. The most stable aristolactam Ia with the lowest relative energy had the most intensive parent ion peak at m/z 280 ( Fig.   6A ), while the least stable N-hydroxyaristolactam II showed intensive fragmentation (Fig.   6B ). Moreover, the MS-MS fragmentations of aristolactam Ia (M6) (Fig. 6A ) and 7-hydroxyaristolactam II (M8) (Fig. 6C) were similar but far more intensive than that of Nhydroxyaristolactam II (M7) (Fig. 6B) , which agreed well with the proposal that M6 and M8 were the same type of (phenolic) compounds, while M7 was different (N-hydroxy).
Similar to AAI, a reductive mechanism for conversing AAII to aristolactam II and related hydroxyaristolactams was suggested. AAII was metabolized to N-hydroxyaristolactam II and then either rearranged to 7-hydroxyaristolactam II via Bamberger rearrangement, or further reduced to aristolactam II. The in vivo metabolic pathway of AAs producing aristolactams and related hydroxylated aristolactams is summarized in Fig. 7 . Because the position of carbon 8 in AAI was blocked by a methoxy group, further oxidation at this position was not possible. Therefore, only two hydroxyaristolactams were produced from AAI while three were produced from AAII, which was in consistent with the experimental results. Identification of the two hydroxylated metabolites of aristolactam I was confirmed with the MS-MS analysis (see the description in "Results").
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